Skip to content

Released May 8, 2025, after the close

10-Q filed May 8, 2025, 38 days after period end · 0000950170-25-067072

Q1 2025 · 10-Q
Revenue$17.40M+33.8% vs Q1 2024+17.5% vs Q4 2024
Net Income-$75.97MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$9.08N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$68,514,000N/M
Operating Cash Flow-$67,883,000N/M
Margins · derived
Operating margin-393.8%+41.3 pt vs Q1 2024
Net margin-436.6%+10.9 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$17.40M$13.01M$12.67M$5.90M
Net Income-$75.97M-$58.21M-$50.05M-$39.11M
EPS Diluted-$9.08-$0.59-$0.85-$0.84

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR